Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Lives in the U.S.~* Able to speak, read and write in English~* Diagnosed with type 2 diabetes~* Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day~* Takes a daily dose ≤ 0.75 units/kg~* Estimated A1c ≥ 8% (based on existing Livongo data)~* Has been enrolled in Livongo for at least 12 weeks~* Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer)~* Willing to complete study questionnaires~* Willing to complete at-home A1c kits~* Willing to check before breakfast blood glucose at least once per day~Exclusion Criteria:~* Diagnosis of type 1 diabetes~* Currently using a long-acting basal insulin analog that is not supported by Insulia~* Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins~* Currently pregnant or planning pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Livongo-Insulia Study App Arm (Type: EXPERIMENTAL): Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration

Based on this trial design, predict the completion outcome and termination type (if applicable).